Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22142027 | 1.00 | HTT (0.38) | HTTOPRD1OPRM1OPRL1HRH3 | |
| SCHEMBL22142105 | 1.00 | HTT (0.38) | HTTOPRD1OPRM1OPRL1HRH3 | |
| SCHEMBL22142055 | 1.00 | HTT (0.38) | HTTOPRD1OPRM1OPRL1HRH3 | |
| SCHEMBL22142193 | 0.87 | GBA1 (0.32) | HTT | |
| SCHEMBL22142186 | 0.87 | GBA1 (0.32) | HTT | |
| SCHEMBL22142303 | 0.87 | GBA1 (0.32) | HTT | |
| SCHEMBL22142187 | 0.87 | GBA1 (0.32) | HTT | |
| SCHEMBL22142390 | 0.87 | GBA1 (0.32) | HTT | |
| SCHEMBL15508579 | 0.81 | LMNA (0.39) | — | |
| SCHEMBL22142679 | 0.79 | HRH3 (0.32) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | HTT 1608/4885OPRD1 2897/4885OPRM1 4508/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | HTT 1608/4885OPRD1 2897/4885OPRM1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.